Characteristics of the 17 included studies investigating FDG-PET
| HD/NHL, study and year . | Patients/scans, no. . | Median age, y (range) . | Sex, M/F . | Criteria for positivity . | Interpreter(s) . |
|---|---|---|---|---|---|
| HD | |||||
| Meany et al,41 2007 | 23/23 | 15 (5-19) | 10/13 | NR | NR |
| Bjurberg et al,42 2006 | 26/34 | NR (8-70) | NR | Any focus of elevated FDG metabolism not located in areas of normal FDG uptake or where the clinical data did not suggest the presence of nonmalignant hypermetabolic lesions. | Two experienced investigators |
| Zinzani et al,43 2006 | 40/40 | 32 (14-48) | 19/21 | Areas of focal uptake, unless they were at the sites of known accumulation, including the kidney and bladder, gastrointestinal tract, skeletal areas showing symmetric uptake (especially in the shoulder) were considered as due to arthritis | Three experienced readers |
| Rigacci et al,38 2005 | 28/28 | 30.6 (16-73) | 14/14 | Foci of hyperactivity outside areas of known physiologic uptake, in comparison with liver and mediastinum | NR |
| Filmont et al,44 2004 | 32/32 | 30 (6-65) | 15/17 | NR | An experienced reader |
| Dittmann et al,45 2001 | 47/47 | NR (18-63) | 27/20 | Focally increased uptake, exceeding that of the surrounding tissue and/or contralateral body regions | Two experienced nuclear medicine physicians |
| NHL | |||||
| Filmont et al,46 2003 | 78/78 | 57 (21-84) | 46/32 | NR | An experienced reader |
| Mikhaeel et al,47 2000 | 45/45 | NR | NR | Residual increased FDG uptake in previously diagnosed disease sites or the appearance of new uptake indicative of progressive disease | Two nuclear medicine physicians |
| Mixed | |||||
| La Fougere et al,39 2006 | 100/100 | NR (19-70) | 24/26 | Regions of focally increased tracer uptake; well-circumscribed areas of tracer uptake in the liver; focal lung lesions identifiable on both attenuation-corrected and noncorrected images; in doubtful cases an SUVmax ≥2.0 | Two board-certified radiologists and nuclear medicine specialists with more than 10 years of experience in CT and PET |
| Hernandez-Pampaloni et al,40 2006 | 16/21 | NR | NR | A focus of increased activity, not corresponding to the known physiologic distribution of FDG | Two experienced nuclear medicine physicians |
| Reinhardt et al,48 2005 | 101/101 | NR | 72/29 | All foci of elevated FDG uptake | NR |
| Freudenberg et al,49 2004 | 27/27 | 46†(19-70) | 16/11 | A SUVmax ≥2.5 in an area of focal tracer uptake | Two experienced nuclear medicine physicians |
| Mikosch et al,50 2003* | 93/121 | NR | NR | NR | NR |
| Mikhaeel et al,51 2000* | 32/32 | NR | 22/10 | Residual tracer uptake | Two independent nuclear medicine physicians |
| Bangerter et al,52 1999 | 36/36 | 31 (17-74) | 16/20 | Any foci of increased FDG uptake over background value that were not located in an area of physiologically increased uptake | Two independent investigators |
| Bangerter et al,53 1999 | 58/58 | NR | NR | Any clearly delineated uptake in the hilar and mediastinal regions | Two nuclear medicine physicians |
| Stumpe et al,54 1998* | 50/71 | NR (17-88) | 31/19 | A focus of increased FDG uptake above the intensity of the background as long as it was outside the renal pelvis, urinary bladder and myocardium | At least 2 board-certified nuclear medicine physicians |
| HD/NHL, study and year . | Patients/scans, no. . | Median age, y (range) . | Sex, M/F . | Criteria for positivity . | Interpreter(s) . |
|---|---|---|---|---|---|
| HD | |||||
| Meany et al,41 2007 | 23/23 | 15 (5-19) | 10/13 | NR | NR |
| Bjurberg et al,42 2006 | 26/34 | NR (8-70) | NR | Any focus of elevated FDG metabolism not located in areas of normal FDG uptake or where the clinical data did not suggest the presence of nonmalignant hypermetabolic lesions. | Two experienced investigators |
| Zinzani et al,43 2006 | 40/40 | 32 (14-48) | 19/21 | Areas of focal uptake, unless they were at the sites of known accumulation, including the kidney and bladder, gastrointestinal tract, skeletal areas showing symmetric uptake (especially in the shoulder) were considered as due to arthritis | Three experienced readers |
| Rigacci et al,38 2005 | 28/28 | 30.6 (16-73) | 14/14 | Foci of hyperactivity outside areas of known physiologic uptake, in comparison with liver and mediastinum | NR |
| Filmont et al,44 2004 | 32/32 | 30 (6-65) | 15/17 | NR | An experienced reader |
| Dittmann et al,45 2001 | 47/47 | NR (18-63) | 27/20 | Focally increased uptake, exceeding that of the surrounding tissue and/or contralateral body regions | Two experienced nuclear medicine physicians |
| NHL | |||||
| Filmont et al,46 2003 | 78/78 | 57 (21-84) | 46/32 | NR | An experienced reader |
| Mikhaeel et al,47 2000 | 45/45 | NR | NR | Residual increased FDG uptake in previously diagnosed disease sites or the appearance of new uptake indicative of progressive disease | Two nuclear medicine physicians |
| Mixed | |||||
| La Fougere et al,39 2006 | 100/100 | NR (19-70) | 24/26 | Regions of focally increased tracer uptake; well-circumscribed areas of tracer uptake in the liver; focal lung lesions identifiable on both attenuation-corrected and noncorrected images; in doubtful cases an SUVmax ≥2.0 | Two board-certified radiologists and nuclear medicine specialists with more than 10 years of experience in CT and PET |
| Hernandez-Pampaloni et al,40 2006 | 16/21 | NR | NR | A focus of increased activity, not corresponding to the known physiologic distribution of FDG | Two experienced nuclear medicine physicians |
| Reinhardt et al,48 2005 | 101/101 | NR | 72/29 | All foci of elevated FDG uptake | NR |
| Freudenberg et al,49 2004 | 27/27 | 46†(19-70) | 16/11 | A SUVmax ≥2.5 in an area of focal tracer uptake | Two experienced nuclear medicine physicians |
| Mikosch et al,50 2003* | 93/121 | NR | NR | NR | NR |
| Mikhaeel et al,51 2000* | 32/32 | NR | 22/10 | Residual tracer uptake | Two independent nuclear medicine physicians |
| Bangerter et al,52 1999 | 36/36 | 31 (17-74) | 16/20 | Any foci of increased FDG uptake over background value that were not located in an area of physiologically increased uptake | Two independent investigators |
| Bangerter et al,53 1999 | 58/58 | NR | NR | Any clearly delineated uptake in the hilar and mediastinal regions | Two nuclear medicine physicians |
| Stumpe et al,54 1998* | 50/71 | NR (17-88) | 31/19 | A focus of increased FDG uptake above the intensity of the background as long as it was outside the renal pelvis, urinary bladder and myocardium | At least 2 board-certified nuclear medicine physicians |
NR indicates not reported; and SUVmax, maximum standardized uptake value.
*This study allowed separate analysis of HD and NHL patients.
†Indicates a mean age.